Why AbbVie Could Join the M&A Mania Soon Post author:Sam Post published:January 30, 2018 Post category:BioPharma The company expects to only pay a tax rate of 9 percent this year, which will free up a lot of cash. Source: BioSpace You Might Also Like Flagship Pioneering Secures $618M for Life Science Startup Mission December 19, 2017 Biotech Startup Rubius to Double Footprint With New Kendall Square Lease February 11, 2018 FDA Formally Rejects Aradigm's Linhaliq, Requests a New Phase III Trial for Reconsideration January 28, 2018
FDA Formally Rejects Aradigm's Linhaliq, Requests a New Phase III Trial for Reconsideration January 28, 2018